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ABSTRACT 34 
Cucurbitacin E is a potential drug candidate due to its anticancer activity, recognition of 35 
its molecular targets, and synergism with other drugs used for cancer treatment. 36 
However, the use of cucurbitacin E in clinical practice is not possible because of 37 
important knowledge gaps in its preclinical and clinical pharmacokinetic characteristics. 38 
Cucurbitacin E is hydrolyzed to cucurbitacin I in plasma and in human liver 39 
microsomes. The aim of this study was to evaluate the population pharmacokinetics of 40 
cucurbitacin E and of its metabolite cucurbitacin I in rats. The method for the sequential 41 
analysis of cucurbitacins E and I in rat plasma was developed using LC-MS/MS. 42 
Plasma aliquots of 50 µL were deproteinized with acetonitrile and clobazam was added 43 
as internal standard. The extracts were injected into an RP-18 column and eluted with a 44 
mobile phase consisting of a mixture of acetonitrile:water:methanol (32:35:33, v/v/v). 45 
The method was precise and accurate, showing linearity in the range of 1-100 ng 46 
cucurbitacin E/mL plasma and of 0.4-200 ng cucurbitacin I/mL plasma. The method 47 
was applied to the pharmacokinetic evaluation of cucurbitacin E administered 48 
intravenously to male Wistar rats (1 mg/kg). Serial blood samples were collected up to 49 
24 h after administration. The plasma concentrations of cucurbitacin E were quantified 50 
up to 16 h, while the plasma concentrations of cucurbitacin I remained below the limit 51 
of quantification. A population pharmacokinetic model was developed for cucurbitacin 52 
E using the NONMEM program, with adequate goodness of fit and predictive 53 
performance. The following pharmacokinetic parameters were obtained: release time of 54 
0.45 h, volume of distribution of 27.22 L, clearance of 4.13 L/h, and elimination half-55 
life of 4.57 h.  56 
 57 
Keywords: cucurbitacin E, cucurbitacin I, rats, LC-MS/MS, population 58 
pharmacokinetics 59 
 60 
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1. INTRODUCTION  67 
Cucurbitacins found mainly in the family Cucurbitaceae are oxygenated 68 
tetracyclic triterpenes [1]. These compounds have a great pharmacological potential 69 
because of their broad spectrum of biological activities such as antimicrobial [2], anti-70 
inflammatory [2,3], anti-HIV [4], antioxidant [5], cytotoxic and antitumor properties 71 
[6,7]. 72 
The current interest in cucurbitacins focuses on their antiproliferative and 73 
cytotoxic potential against a large number of human cancer cell lines, including colon, 74 
breast, liver, skin, lung, central nervous system, prostate, and nasopharyngeal cancer [6-75 
11]. In this respect, promising targets of cucurbitacins in cancer therapy are being 76 
identified, including inhibition of the JAK2/STAT3 signaling pathway [12-14], rupture 77 
of the cytoskeletal actin and vimentin networks [12-13].  78 
Although neglected for decades, cucurbitacin E (Figure 1) has gained special 79 
attention of many research groups due to its promising anticancer activity [8, 10, 12-80 
13]. Its ability to disrupt the cytoskeleton and to inhibit the JAK2-STAT3 pathway, 81 
among other mechanisms, and the synergisms with other drugs used in cancer therapy 82 
have rendered cucurbitacin E a candidate for clinical evaluation [6, 9,15].  83 
Preliminary studies on the metabolism of cucurbitacins have shown that 84 
cucurbitacin E is hydrolyzed to cucurbitacin I (Figure 1) in human plasma by 85 
paraoxonase [16] and in human liver microsomes by carboxylesterases [17]. The 86 
analytical methods for cucurbitacins described in the literature generally use plant 87 
extracts [11,16,18], buffer solutions and organic solvents [16,19] and HPLC with 88 
ultraviolet detection. The analysis of cucurbitacins in biological fluids is only described 89 
for cucurbitacin B in rat plasma by UPLC-MS/MS [20] and for cucurbitacin I in rat 90 
plasma using LC-MS [21]. No data are available regarding the development and 91 
validation of analytical methods for cucurbitacin E in biological fluids. 92 
The present study reports for the first time the development and validation of a 93 
sequential analytical method for cucurbitacin E and its metabolite cucurbitacin I in rat 94 
plasma using LC-MS/MS. The analytical method was applied to pharmacokinetic 95 
studies of cucurbitacins E and I in rats. We also describe for the first time the 96 
development of a population pharmacokinetic model of cucurbitacin E in rats.  97 
 98 
2. MATERIAL AND METHODS 99 
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2.1. Development and validation of a sequential analytical method for cucurbitacin 100 
E and cucurbitacin I in rat plasma 101 
2.1.1 Chemicals and reagents 102 
The cucurbitacin E (≥ 95%) and cucurbitacin I (≥ 95%) standards, clobazam 103 
(internal standard) (Figure 2), and dimethylsulfoxide (DMSO) were purchased from 104 
Sigma (St. Louis, MO, USA). All solvents used were of HPLC grade. Methanol, 105 
acetonitrile, sodium chloride, monobasic sodium phosphate, and dibasic sodium 106 
phosphate were purchased from Merck (Darmstadt, Germany). Isopropanol was 107 
purchased from Fisher Scientific (Fair Lawn, NJ, USA). The water used in the 108 
experiments was purified with the Synergy
®
 UV water purification system (Millipore, 109 
Belford, MA, USA). 110 
 111 
2.1.2 Chromatographic analysis 112 
Cucurbitacin E and cucurbitacin I were analyzed by liquid chromatography 113 
coupled to tandem mass spectrometry (LC-MS/MS) using the Acquity UPLC H-Class 114 
System
®
, which consists of a quaternary pump, column oven and automatic injector, 115 
coupled to a Xevo
®
 TQ-S triple quadrupole detector (Waters, Milford, MA, USA). 116 
Cucurbitacin E, cucurbitacin I and clobazam (internal standard) were separated on a 117 
Chromolit
®
 RP-18 column (100 x 4.6 mm, 4-µm particle size) maintained at 24ºC. The 118 
mobile phase consisted of a mixture of acetonitrile:water:methanol (32:35:33; v/v/v) 119 
eluted at a flow rate of 0.8 mL/min.  120 
The tandem mass spectrometer with electrospray ionization operated under the 121 
following conditions: nitrogen as nebulizer gas at a flow rate of 150 L/h and argon as 122 
collision gas at a flow rate of 0.18 mL/min, capillary voltage of 2.5 kV, temperature of 123 
the ionization source of 150ºC, and desolvation temperature of 600ºC. The analyses 124 
were performed by multiple reactions monitoring (MRM) in the negative mode for 125 
cucurbitacin E (555.2>537.3 m/z) and cucurbitacin I (513.4>495.3 m/z) and in the 126 
positive mode for clobazam (301.0>256.0 m/z). The MassLynx 4.1 program (Waters, 127 
Milford, MA, USA) was used for data acquisition and samples quantification. 128 
 129 
2.1.3 Preparation of the standards and quality controls 130 
Stock solutions of cucurbitacin E and cucurbitacin I were prepared at a 131 
concentration of 100 µg/mL methanol and diluted to obtain working solutions of  2, 4, 132 
8, 20, 40, 80, 160 and 200 ng cucurbitacin E/mL methanol and of 0.8, 1.6, 4, 10, 20, 40, 133 
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100, 160, 320 and 400 ng cucurbitacin I/mL methanol. The clobazam solution (internal 134 
standard) was prepared at a concentration of 1000 g/mL methanol and diluted to 500 135 
ng/mL methanol.  136 
The calibration curves were constructed using 50-µL blank rat plasma spiked 137 
with 25 µL of each standard solution of cucurbitacin E and cucurbitacin I, resulting in 138 
concentrations of 1, 2, 4, 10, 20, 40, 80 and 100 ng cucurbitacin E/mL plasma and of 139 
0.4, 0.8, 2, 5, 10, 20, 50, 80, 160 and 200 ng cucurbitacin I/mL plasma.  140 
The quality controls (QC) were prepared using aliquots of blank plasm spiked 141 
with the standard solutions of cucurbitacin E and cucurbitacin I. The following QC 142 
samples were prepared: lower limit of quantification (LLOQ; 1.0 ng/mL for 143 
cucurbitacin E and 0.4 ng/mL for cucurbitacin I), low concentration (LQC; 2.0 ng/mL 144 
for cucurbitacin E and 0.8 ng/mL for cucurbitacin I), medium concentration (MQC; 40 145 
ng/mL for cucurbitacin E and 80 ng/mL for cucurbitacin I), and high concentration 146 
(HQC; 80.0 ng/mL for cucurbitacin E and 160 ng/mL for cucurbitacin I). 147 
 148 
2.1.4 Sample preparation 149 
Aliquots (50 µL) of rat plasma were added to 100 µL acetonitrile for protein 150 
precipitation. The tubes were shaken for 30 s in a shaker and centrifuged at 6,000 rpm 151 
for 2 min at 5
o
C. Next, 100 µL aliquots of the supernatants were transferred to vials of 152 
the automatic injector of the HPLC system and 100 µL of a mixture of 153 
acetonitrile:water (1:1, v/v) and 25 μL of the internal standard solution were added. The 154 
vials were shaken in a shaker for 30 s and 50 µL aliquots were injected into the 155 
chromatographic system for analysis.  156 
 157 
2.1.5 Validation of the analytical method  158 
The analytical method for cucurbitacin E and cucurbitacin I in rat plasma was 159 
validated according to the guidelines of the European Medicines Agency (EMEA) [22] 160 
for bioanalytical methods. The following parameters were evaluated: lower limit of 161 
quantitation, selectivity, carry-over, matrix effect, linearity, precision, accuracy and 162 
stability. 163 
The method was validated using aliquots of blank plasma derived from blood 164 
samples of male Wistar rats not submitted to the experimental protocol as biological 165 
matrix (blank sample). The blood samples were collected using heparin as 166 
anticoagulant. 167 
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Calibration curves (n= 6) were obtained by spiking aliquots of 50 μL blank 168 
plasma samples with cucurbitacin E and I standard solutions. The calibration curve was 169 
constructed by plotting the cucurbitacin E and I/IS peak area versus cucurbitacin E and I 170 
concentrations. The correlation coefficient (r) and linear regression equation were 171 
calculated using the linear regression method (1/x
2
). The lower limit of quantitation 172 
(LLOQ) was defined as the lowest concentration of cucurbitacin E and I in plasma 173 
quantified with acceptable accuracy and precision (coefficient of variation and percent 174 
inaccuracy of less than 20%). 175 
Carry-over was assessed by directly injecting an extracted blank after both 176 
replicates of the upper limit of quantification of cucurbitacin E and I. 177 
 The matrix effect was assessed by direct comparison of the peak areas of 178 
cucurbitacin E and I and the internal standard injected directly into the mobile phase, 179 
and spiked into extracts originating from six diferente sources of rat plasma. The IS 180 
normalized matrix factor was calculated for each matrix lot by dividing the ratio of the 181 
analyte/IS response in the presence of matrix by the ratio of the analyte/IS response in 182 
the absence of matrix. The coefficient of variation for the IS normalized matrix factor 183 
should be less than 15%. 184 
Precision and accuracy were evaluated by intra and inter-assay studies. Six 185 
replicates of quality control samples were evaluated in a single analytical run (intra-186 
assay) and in three different runs on different days (inter-assay). Precision is reported as 187 
the coefficient of variation (CV), that must be equal to or less than 15%, except for 188 
LLOQ, for which it should be up to 20%. Accuracy is determined by percent 189 
inaccuracy, excluding values higher than 15% of the nominal value, except for LLOQ, 190 
for which values higher than 20% of the nominal concentration should be excluded. 191 
The stability of the cucurbitacin E and I was guaranteed by two freeze (-70 
◦
C) 192 
and thaw (25 
◦
C) cycles lasting 12 h each and by the evaluation of short-term stability (4 193 
h at room temperature, 25 
◦
C) and postprocessing stability (12 
◦
C for 12 h). For this 194 
purpose, blank plasma samples spiked with cucurbitacin E and I concentrations of LQC 195 
and HQC ng/mL plasma were analyzed in six replicates. The results of the stability tests 196 
are reported as accuracy in relation to freshly prepared samples. The samples were 197 
considered stable when the relative error (RER, %) from the nominal concentration was 198 
within ±15% and when the CV was below 15%. 199 
 200 
 201 
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2.2. Population pharmacokinetics of cucurbitacin E in rat plasma 202 
2.2.1. Experimental protocol 203 
Male Wistar rats weighing 200-300 g, obtained from the Animal House of the 204 
Faculty of Pharmaceutical Sciences of Ribeirão Preto, were used. The procedures were 205 
approved by the Ethics Committee on Animal Use of the University of São Paulo 206 
(Protocol CEUA USP 12.1.1382.53.9). 207 
The cucurbitacin E solution administered to the animals was prepared at a 208 
concentration of 0.4 mg/mL in a mixture (5:95, v/v) of DMSO and phosphate-buffer 209 
saline (67 mM, pH 7.4). The animals (n = 6 per sampling time) were treated with a 210 
single intravenous dose (1 mg/kg) of cucurbitacin E. Serial blood samples of 200 µL (3-211 
4 samples per animal) were collected of the tail vein of each animal at time zero, 5, 15, 212 
30 and 45 min and 1, 2, 3, 4, 6, 8, 12, 16 and 24 h after the cucurbitacin administration. 213 
In this study were used 36 animals. The blood samples were transferred to tubes 214 
containing heparin and immediately centrifuged (2 min, 6000 rpm, 5
o
C) for the 215 
separation of plasma. The plasma aliquots were immediately analyzed using the method 216 
described in item 2.1.4. 217 
 218 
2.2.2. Development of the population pharmacokinetic model 219 
For evaluation of population pharmacokinetics, a nonlinear model of mixed 220 
effects was developed with the NONMEM v.7.3 program (ICON Development 221 
Solutions, Ellicott City, MD, USA) in the first-order conditional estimation mode with 222 
the interaction option (FOCE-I) [23] using a GNU Fortran 4.6 compiler (Free Software 223 
Foundation, Inc.) and PsN interface, version 4.4.0 (Perl-speaks-NONMEM, University 224 
of Uppsala, Sweden) [24].  225 
Model building criteria included successful minimization without termination of 226 
the covariance step, standard error of estimates and absence of correlation between 227 
parameter estimates. Comparison of hierarchical models was based on the objective 228 
function (OF) value. A parameter was considered statistically relevant and included in 229 
the model if it decreased the OF more than 3.84 (p=0.05), following the assumption that 230 
the change in the OF after the addition of a parameter approximate a 2 distribution with 231 
one degree of freedom. Goodness of fit was assessed by graphical methods, including 232 
population and individual predicted vs. observed concentrations, conditional weighted 233 
residuals vs. population predicted concentrations and time. 234 
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The samples below the limit of quantification (BQL) were retained for model 235 
building purposes. These samples were analyzed by modelling the probability that they 236 
are actually below the limit of quantification [25].   237 
The model was evaluated for its predictive performance using graphical criteria, 238 
as assessed by visual predictive check based on 1,000 individual simulations of plasma 239 
concentrations vs. time. The confidence intervals around the median 5% and 95% 240 
intervals of the simulated concentrations were plotted together with the observed data to 241 
visually evaluate the fit of the model to the data, its precision, and predictive 242 
performance.  243 
 244 
3. RESULTS AND DISCUSSION 245 
3.1. Development and validation of the sequential analytical method for 246 
cucurbitacin E and cucurbitacin I in rat plasma 247 
The present study describes for the first time the development and validation of a 248 
method using LC-MS/MS for the analysis of cucurbitacin E in rat plasma and the first 249 
sequential analytical method for cucurbitacin and its metabolite using LC-MS/MS. 250 
The analytical method for cucurbitacin E and cucurbitacin I in rat plasma 251 
permitted the sequential analysis of both cucurbitacins, with a chromatographic run time 252 
of 6 min. The lowers limits of quantification (LLOQ) were 0.4 ng cucurbitacin I and 1.0 253 
ng cucurbitacin E/mL plasma using plasma aliquots of only 50 µL (Figure 3). It should 254 
be noted that the limit of quantification obtained for cucurbitacin I was 25 times lower 255 
than that reported in the literature (10 ng/mL plasma) by Molavi et al., 2006 [21]. 256 
Tables 1 and 2 show the results of linearity, LLOQ, precision and accuracy 257 
obtained in the validation of the sequential analytical method for cucurbitacin E and 258 
cucurbitacin I, respectively, in rat plasma. The validated method showed no matrix 259 
effect, considering that the coefficients of variation obtained for all matriz factor (MF) 260 
values were less than 15%. Analysis of different blank plasma samples revealed the 261 
absence of interference of endogenous compounds with cucurbitacin E, cucurbitacin I 262 
and internal standard, indicating adequate selectivity. The two blank plasma samples 263 
analyzed immediately after injection of the upper limit of quantification (ULOQ) 264 
sample exhibited no residual effect. Coefficients of variation and standard errors of less 265 
than 15% were obtained in the precision (CV=9.6%) and accuracy (RSE=10.3%) 266 
studies (Table 1 and Table 2), indicating that the method is accurate and precise. 267 
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Stability tests showed that cucurbitacin E and cucurbitacin I are stable for 30 268 
days when prepared in methanol (stability testing in solution). With respect to the 269 
stability of cucurbitacin E and cucurbitacin I in rat plasma, the samples were stable after 270 
two freeze-thaw cycles, at room temperature for up to 4 h, after processing for 12 h at 271 
12ºC, and during storage at -70ºC for a period of 30 days. 272 
The validated sequential analytical method for cucurbitacin E and cucurbitacin I 273 
in rat plasma was applied to investigate the population pharmacokinetics of cucurbitacin 274 
E and its metabolite cucurbitacin I in rats.  275 
 276 
3.2. Plasma concentrations of cucurbitacin E and its metabolite cucurbitacin I in 277 
rat plasma samples 278 
The administration of a single intravenous dose of 1 mg/kg cucurbitacin E to rats 279 
resulted in plasma concentrations of cucurbitacin E above the LLOQ up to 16 h after 280 
administration. Figure 4 shows the chromatograms obtained for the analysis of a plasma 281 
sample collected 3 h after intravenous administration of 1 mg/kg cucurbitacin E to a rat. 282 
However, the plasma concentrations of cucurbitacin I remained below the LLOQ (0.4 283 
ng/mL plasma) in all samples collected up to 24 h after the administration of 284 
cucurbitacin E. 285 
Studies on the metabolism of cucurbitacin E in human liver microsomes and in 286 
human plasma have shown the formation of cucurbitacin I [17,16]. Saade et al. (2009) 287 
[16] suggested the participation of paraoxonase in the hydrolysis of cucurbitacin E to 288 
cucurbitacin I in human plasma. However, the concentrations of esterases in human 289 
plasma differ from those found in rat plasma; for example, the concentration of 290 
paraoxonase is 2-fold higher in human plasma than in rat plasma [26]. Thus, it is 291 
possible that rat plasma is unable to hydrolyze cucurbitacin E to cucurbitacin I, a fact 292 
that would explain the plasma concentrations of cucurbitacin I below the LLOQ in the 293 
study of intravenous administration of cucurbitacin E to rats. 294 
 295 
3.3. Development and validation of the population pharmacokinetic model of 296 
cucurbitacin E in rat plasma after intravenous administration 297 
This is the first study describing a population pharmacokinetic model for the 298 
class of cucurbitacins, particularly cucurbitacin E administered intravenously. The 299 
plasma concentration-time profile of cucurbitacin E after a single intravenous dose 300 
administration to rats (Figure 5) and the release time (D) of 0.45 h estimated with the 301 
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population pharmacokinetic model (Table 3) show that the pharmacokinetic behavior of 302 
cucurbitacin E resembles more a controlled release or infusion profile rather than the 303 
bolus intravenous administration used in the experimental study. Based on this 304 
observation, the population pharmacokinetic model of cucurbitacin E was developed 305 
assuming administration as an intravenous infusion. An overview of the goodness-of-fit 306 
is shown in the Figure 6. The plots show that individually predicted concentrations are 307 
unbiased and that residual errors are randomly distributed around mean zero. 308 
Cucurbitacin E is not soluble in polar solvents and therefore requires prior 309 
solubilization in DMSO followed by dilution in phosphate-buffered saline. When 310 
diluted in aqueous buffer, analytes soluble in DMSO form a homogenous solution, a 311 
homogenous suspension, or a heterogenous suspension with the observation of 312 
precipitation [27]. The behavior of cucurbitacin E in the phosphate buffer-DMSO 313 
mixture (95:5, v/v) at the concentration used in the pharmacokinetic study (0.4 mg 314 
cucurbitacin E/mL) resembles a homogenous suspension, a fact explaining the release 315 
time of 0.45 h after intravenous administration. Concentrations higher than 0.4 mg 316 
cucurbitacin E/mL were not used because of the change from a homogenous suspension 317 
to a heterogenous suspension.  318 
An overview of the goodness-of-fit is shown in the Figure 6. The plots show that 319 
individually predicted concentrations are unbiased and that residual errors are randomly 320 
distributed around mean zero. The high conditional weighted residuals shown are a 321 
consequence the high inter-individual and experimental variability of the data in 6 322 
subjects. This variability led the predicted concentrations to deviate considerably from 323 
the observed concentrations. However, these deviations have not affected the estimation 324 
of the pharmacokinetic parameters. In fact, the model parameter estimates proved to be 325 
robust. During the analysis, the exclusion of the outliers resulted in estimates values 326 
similar to the ones obtained with the full data set. 327 
Figure 7 illustrates the visual predictive check of the population pharmacokinetic 328 
model of cucurbitacin E in rat plasma after intravenous administration. Additionally, the 329 
figure indicates the percentage of BQL samples for each sample time, in case they are 330 
present, to highlight their influence on the prediction of the drug concentrations. The 331 
pharmacokinetic profile of the median plasma concentrations of cucurbitacin E was 332 
described by a two-compartment model with first-order distribution and elimination. 333 
The pharmacokinetic parameter estimates, interindividual variability, residual 334 
variability of the model and relative standard deviation (RSD%) of these estimates are 335 
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shown in Table 3 for release time (D), volume of distribution from the central 336 
compartment (Vc) and from the peripheral compartment (Vp), clearance (Cl), and 337 
intercompartmental clearance (Q).  338 
The population pharmacokinetic profile of cucurbitacin E administered 339 
intravenously to rats (Table 3) suggests the need to develop formulations that result in a 340 
solubility compatible with the requirements of preclinical pharmacokinetic studies. 341 
Additionally, studies on the metabolism of cucurbitacin E and in vitro membrane 342 
transporters using human cells are necessary.  343 
 344 
4. CONCLUSION  345 
The sequential analytical method for cucurbitacin E and cucurbitacin I in rat 346 
plasma using LC-MS/MS is precise, accurate and sensitive, permitting its application to 347 
preclinical pharmacokinetic studies of single intravenous dose. The cucurbitacin I 348 
plasma concentrations remained below the LLOQ in all samples collected after 349 
intravenous administration of cucurbitacin E. It is possible that rat plasma is unable to 350 
hydrolyze cucurbitacin E to cucurbitacin I because of differences in esterase 351 
concentrations between human and rat plasma.  352 
The pharmacokinetic profile of cucurbitacin E administered intravenously to rats 353 
was described by a two-compartment model with first-order distribution and elimination 354 
and the following pharmacokinetic parameters were obtained: volume of distribution of 355 
27.22 L, clearance of 4.13 L/h, and elimination half-life of 4.57 h. In addition, the 356 
pharmacokinetic behavior of cucurbitacin E administered intravenously to rats 357 
resembled an infusion, with a release time of 0.45 h due to the low solubility of 358 
cucurbitacin E prepared in a mixture of phosphate-buffered saline (pH 7.4) and DMSO 359 
(95:5, v/v). 360 
 361 
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Figure 1. Chemical structure of cucurbitacin E and cucurbitacin I. 
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Figure 2. Chemical structure of clobazam (internal standard). 
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Figure 3. Representative MRM chromatograms for cucurbitacin E and cucurbitacin I. 
(A) Chromatogram of rat plasma spiked with 1.0 ng/mL (LLOQ) of cucurbitacin E; (B) 
Chromatogram of blank plasma monitored in the transition of cucurbitacin E 
(555.2>537.3); (C) Chromatogram of rat plasma spiked with 0.4 ng/mL (LLOQ) of 
cucurbitacin I; (D) Chromatogram of blank plasma monitored in the transition of 
cucurbitacin I (513.4>495.3).  
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Figure 4. Chromatograms obtained for the analysis of a plasma sample collected 3 h 
after intravenous administration of cucurbitacin E (1 mg/kg) to a Wistar rat. (A) 
Chromatogram showing the transition of cucurbitacin E (555.2>537.3). (B) 
Chromatogram showing the transition of cucurbitacin I (513.4>495.3). (C) 
Chromatogram showing the transition of clobazam (internal standard) (301.0>224.0). 
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Figure 5. The plasma concentration-time profile of cucurbitacin E after a single 
intravenous dose administration to rats. 
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Figure 6. Goodness-of-fit. The plots show that individually predicted concentrations are 
unbiased and that residual errors are randomly distributed around mean zero. 
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Figure 7. Visual predictive check. The observed plasma concentrations are shown as 
dots. The solid line represents the median of the observed plasma concentrations. The 
dotted lines indicate the 5
th
 and 95
th
  percentiles of the observed plasma concentrations. 
The dark grey shaded area represents the confidence interval around the median of the 
predicted plasma concentrations. The light grey shaded areas show the confidence 
interval around the 5
th
 and 95
th
 percentiles of the predicted plasma concentrations.  
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Table 1. Validation parameters of the analytical method for cucurbitacin E in rat 
plasma. 
Parameter    
Linearity (ng/mL) 1.0 - 100.0  
Straight-line equation y=0.0277031x+0.0352023  
Linear correlation 
coefficient 
r=0.991606 
 
 
 
        
 
(ng/mL) 
Measured 
concentration 
(ng/mL) ± S.D 
Between-run 
precision (n=18) 
(CV %) 
Within-run 
precision (n=6) 
(CV %) 
1.0   1.12 ± 0.13 12.78 7.26 
2.0   2.17 ± 0.20 9.59 10.06 
40.0 
80.0 
39.10 ± 1.11 
82.34 ± 3.24 
8.71 
13.85 
12.2 
13.43 
    
 Measured 
concentration 
(ng/mL) ± S.D 
Between-run 
accuracy (n=18) 
(RSE %) 
Within-run 
accuracy (n=6) 
(RSE %) 
1.0   1.01 ± 0.07 10.66 1.6 
2.0   2.04 ± 0.05 7.87 3.0 
40.0 
80.0 
40.24 ± 0.68 
79.32 ± 1.56 
4.72 
-5.8 
4.47 
2.1 
CV: coefficient of variation [(standard deviation/mean) x 100]; RSE: relative standard error 
[(mean - nominal value)/nominal value x 100]; r: linear correlation coefficient. 
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Table 2. Validation parameters of the analytical method for cucurbitacin I in rat plasma. 
Parameter   
Linearity (ng/mL) 0.4 - 200.0  
Straight-line equation y=0.00202823x+0.00490914  
Linear correlation 
coefficient 
r=0.993945 
 
 
        
 
(ng/mL) 
Measured 
concentration 
(ng/mL) ± S.D 
Between-run 
precision (n=18) 
(CV %) 
Within-run 
precision (n=6) 
 (CV %) 
0.4   0.48 ± 0.12 9.32 12.45 
0.8   0.76 ± 0.22 11.2 9.15 
80.0 
160.0 
83.12 ± 3.18 
164.73 ± 6.43 
7.9 
10.34 
11.3 
8.64 
    
 Measured 
concentration 
(ng/mL) ± S.D 
Between-run 
accuracy (n=18) 
(RSE %) 
Within-run 
accuracy (n=6) 
(RSE %) 
0.4   0.35 ± 0.09 8.65 8.45 
0.8   0.87 ± 0.56 7.6 9.5 
80.0 
160.0 
81.12 ± 4.03 
162.17 ± 9.56 
10.15 
11.25 
6.8 
-5.4 
CV: coefficient of variation [(standard deviation/mean) x 100]; RSE: relative standard error 
[(mean - nominal value)/nominal value x 100]; r: linear correlation coefficient. 
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Table 3. Estimates of the population pharmacokinetic model of cucurbitacin E (1 
mg/kg) administered intravenously to rats. 
 Typical value  
() 
RSD% 
IIV 
(CV%) 
RSD% 
Clearance (L/h) 4.13 5.1% 28.8% 6.6% 
Vc (L) 0.815 14.2% -- -- 
Q (L/h) 110 9.7% 48.7% 9.8% 
Vp (L) 26.4 6.2% -- -- 
D (h) 0.452 8.6% -- -- 
 2    
 0.562 9.2% -- -- 
Vc: central volume of distribution; Q: intercompartmental clearance; Vp: peripheral 
volume of distribution; D: release time; IIV: interindividual variability (expressed as the 
coefficient of variation: CV(%) = √ω ∙ 100); 2: variance of arwhere     F   F    ); 
RSD%: relative standard deviation. 
 
